Prime Medicine to Present at Upcoming Investor Conferences
News provided byPrime Medicine, Inc.
Sep 19, 2023, 8:00 AM ET
Cambridge, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at three upcoming investor conferences:
- BMO Biopharma Virtual Spotlight Series: Latest Advances in Genome / Epigenome Editing: Fireside chat on Tuesday, September 26, 2023, at 10:30 a.m. ET.
- Jefferies Cell & Genetic Medicine Summit (New York, NY): Fireside chat on Wednesday, September 27, 2023, at 9:00 a.m. ET.
- Chardan’s 7th Annual Genetic Medicines Conference (New York, NY):
- Fireside chat on Tuesday, October 3, 2023, at 2:30 p.m. ET.
- Panel discussion, “Next-Gen Genome Editing,” on Tuesday, October 3, 2023, at 4:00 pm ET.
Live audio webcasts of the Jefferies and Chardan fireside chats will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. In addition, replays of the BMO fireside chat and Chardan panel discussion will become available after the presentations conclude. Replays of all webcasts will be available on the Prime Medicine website for 30 days following the presentation.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types.
Prime Medicine is currently progressing a diversified portfolio of eighteen programs initially focused on genetic diseases with a fast, direct path to treating patients or with a high unmet need because they cannot be treated using other gene-editing approaches. Over time, the Company intends to maximize Prime Editing’s therapeutic potential and advance potentially curative therapeutic options to patients for a broad spectrum of diseases. For more information, please visit www.primemedicine.com.
© 2023 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
Stern Investor Relations, Inc.
Dan Budwick, 1AB
NOTE: This content is not written by or endorsed by "KRON", its advertisers, or Nexstar Media Inc.